Investigational drug · Phase 2
BG1805
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Leukemia, Myeloid, Acute.
Phase 2Last checked: Nov 19, 2026Latest source record: Apr 17, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "BG1805"
First trial start
2024
Mar 7, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BG1805", any sponsor or status.
Conditions studied
As listed on its trial records.
- Leukemia, Myeloid, Acute
Approved drugs for the same conditions: Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "BG1805" as an intervention, largest first.
- BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia in ChildrenNot yet recruiting
Guangzhou Bio-gene Technology Co., LtdIndustry
NCT06347458 · 24 participants (planned) · Start Apr 2024 · Primary completion Apr 2027
Drug: BG1805 · For: Leukemia; Acute Myeloid Leukemia
Guangzhou Bio-gene Technology Co., LtdIndustry
NCT06118788 · 24 participants (planned) · Start Mar 7, 2024 · Primary completion Mar 2027
Drug: BG1805 · For: Leukemia, Myeloid, Acute
Sites: Guangzhou, China; Hangzhou, China · 3 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Leukemia, Myeloid, Acute
- BleximenibJNJ-75276617Phase 32 trials
Johnson & Johnson (Janssen) · Acute Leukemia, Leukemia, Myeloid, Acute
- CusatuzumabOV-1001, JNJ-74494550Phase 22 trials
OncoVerity, Inc. · Leukemia, Myeloid, Acute
- AG-120Phase 21 trial
Bristol Myers Squibb · Leukemia, Myeloid, Acute
- AG-221Phase 21 trial
Bristol Myers Squibb · Leukemia, Myeloid, Acute
- TuspetinibHM43239Phase 21 trial
Aptose Biosciences Inc. · Leukemia, Myeloid, Acute, Refractory AML, Relapsed Adult AML
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.